menu
    • menu
    [{"orgOrder":0,"company":"Targovax","sponsor":"Innovation Norway","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"Apricoxib","moa":"||Cyclooxygenase-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Targovax \/ Innovation Norway","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/ Innovation Norway"},{"orgOrder":0,"company":"Targovax","sponsor":"IOVaxis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2020","type":"Licensing Agreement","leadProduct":"Apricoxib","moa":"||Cyclooxygenase-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Injection","sponsorNew":"Targovax \/ IOVaxis Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/ IOVaxis Therapeutics"},{"orgOrder":0,"company":"Targovax","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Targovax \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/ AstraZeneca"},{"orgOrder":0,"company":"Targovax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Targovax \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/ Inapplicable"},{"orgOrder":0,"company":"Targovax","sponsor":"Agenus","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"ONCOS-102","moa":"GM-CSF","graph1":"Oncology","graph2":"Phase II","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Targovax \/ Agenus","highestDevelopmentStatusID":"8","companyTruncated":"Targovax \/ Agenus"},{"orgOrder":0,"company":"Targovax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase II","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Targovax \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Targovax \/ Inapplicable"},{"orgOrder":0,"company":"Targovax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase II","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Targovax \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Targovax \/ Inapplicable"},{"orgOrder":0,"company":"Targovax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Targovax \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/ Inapplicable"},{"orgOrder":0,"company":"Targovax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Targovax \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/ Inapplicable"},{"orgOrder":0,"company":"Targovax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Targovax \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/ Inapplicable"},{"orgOrder":0,"company":"Targovax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Targovax \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/ Inapplicable"},{"orgOrder":0,"company":"Targovax","sponsor":"Theradex Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Targovax \/ Theradex Oncology","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/ Theradex Oncology"},{"orgOrder":0,"company":"Targovax","sponsor":"Oblique Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Targovax \/ Targovax","highestDevelopmentStatusID":"4","companyTruncated":"Targovax \/ Targovax"},{"orgOrder":0,"company":"Targovax","sponsor":"Valo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"ONCOS-102","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Targovax \/ Targovax","highestDevelopmentStatusID":"4","companyTruncated":"Targovax \/ Targovax"},{"orgOrder":0,"company":"Targovax","sponsor":"Leidos","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"||Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Targovax \/ Targovax","highestDevelopmentStatusID":"1","companyTruncated":"Targovax \/ Targovax"},{"orgOrder":0,"company":"Targovax","sponsor":"Targovax","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Apricoxib","moa":"Cyclooxygenase-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Powder for Injection","sponsorNew":"Targovax \/ Targovax","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/ Targovax"},{"orgOrder":0,"company":"Targovax","sponsor":"Targovax","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"TG01 Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Targovax \/ Targovax","highestDevelopmentStatusID":"8","companyTruncated":"Targovax \/ Targovax"},{"orgOrder":0,"company":"Targovax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Targovax \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/ Inapplicable"},{"orgOrder":0,"company":"Targovax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Targovax \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/ Inapplicable"},{"orgOrder":0,"company":"Targovax","sponsor":"IOVaxis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2021","type":"Licensing Agreement","leadProduct":"Apricoxib","moa":"Cyclooxygenase-2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Targovax \/ IOVaxis Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Targovax \/ IOVaxis Therapeutics"},{"orgOrder":0,"company":"Targovax","sponsor":"Agenus","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"Apricoxib","moa":"||Cyclooxygenase-2","graph1":"Oncology","graph2":"IND Enabling","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Targovax \/ Agenus","highestDevelopmentStatusID":"5","companyTruncated":"Targovax \/ Agenus"}]

    Find Clinical Drug Pipeline Developments & Deals by Targovax

    Menu

    Targovax

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Targovax

                            Norway arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Targovax

                            Norway arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Apricoxib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : Oslo University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple My...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            May 03, 2023

                            Lead Product(s) : Apricoxib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Oslo University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Targovax

                            Norway arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Targovax

                            Norway arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TG01 Vaccine

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : University of Kansas Medical Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tg01 Vaccine / Qs-21 Stimulonâ„¢ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Che...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            December 06, 2022

                            Lead Product(s) : TG01 Vaccine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : University of Kansas Medical Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Targovax

                            Norway arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Targovax

                            Norway arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Apricoxib,Gemcitabine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Innovation Norway

                            Deal Size : $0.9 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Innovation Norway Awards NOK 8.2 mn Grant to Targovax for Development of TG Mutant RAS Vaccine

                            Details : With the support from Innovation Norway, Targovax has move the TG program forward faster and more broadly, and thus bring benefit to a patient group with poor prognosis and few available treatment options.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            December 01, 2022

                            Lead Product(s) : Apricoxib,Gemcitabine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Innovation Norway

                            Deal Size : $0.9 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Targovax

                            Norway arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Targovax

                            Norway arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ONCOS-102

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Agenus

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of ONCOS-102 in Combination With Other Novel Immune-therapies in Advanced Treatment-resistant Melanoma...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Microorganism

                            Upfront Cash : Inapplicable

                            September 30, 2022

                            Lead Product(s) : ONCOS-102

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Agenus

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Targovax

                            Norway arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Targovax

                            Norway arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Apricoxib,QS-21 Stimulon

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Agenus

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Targovax ASA and Agenus Announce Collaboration on Mutant KRAS Cancer Vaccine Adjuvanted With QS-21 STIMULON™

                            Details : Under the collaboration with Targovax, Agenus will supply QS-21 STIMULON and scientific support for up to three initial TG01 clinical trials in different cancer indications.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            July 03, 2022

                            Lead Product(s) : Apricoxib,QS-21 Stimulon

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Agenus

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Targovax

                            Norway arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Targovax

                            Norway arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ONCOS-102,Carboplatin,Cyclophosphamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Targovax’s ONCOS-102 Mesothelioma 24-month Data Shows Class-leading Median Overall Survival

                            Details : The study is an open-label, exploratory phase 1/2 trial adding ONCOS-102 to SoC chemotherapy (pemetrexed/cisplatin) in first- and second- (or later) line MPM to assess safety, immune activation and clinical efficacy compared with SoC alone.

                            Product Name : Undisclosed

                            Product Type : Microorganism

                            Upfront Cash : Inapplicable

                            October 06, 2021

                            Lead Product(s) : ONCOS-102,Carboplatin,Cyclophosphamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Targovax

                            Norway arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Targovax

                            Norway arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ONCOS-102,Cisplatin,Pemetrexed

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Targovax Granted European Patent for ONCOS-102 in Combination with Chemotherapy

                            Details : The patent covers the use of ONCOS-102 in combination with chemotherapy in malignant pleural mesothelioma. ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune sys...

                            Product Name : Undisclosed

                            Product Type : Microorganism

                            Upfront Cash : Inapplicable

                            September 24, 2021

                            Lead Product(s) : ONCOS-102,Cisplatin,Pemetrexed

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Targovax

                            Norway arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Targovax

                            Norway arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ONCOS-102,Cyclophosphamide,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            US FDA Grants Fast Track Status To Targovax ONCOS-102 to Treat Refractory Advanced Melanoma

                            Details : The US FDA has granted Fast Track designation to ONCOS-102 based on the current pre-clinical and clinical data package, including mechanistic evidence showing an association between ONCOS-102-induced immune activation and tumor responses.

                            Product Name : Undisclosed

                            Product Type : Microorganism

                            Upfront Cash : Inapplicable

                            June 24, 2021

                            Lead Product(s) : ONCOS-102,Cyclophosphamide,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Targovax

                            Norway arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Targovax

                            Norway arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ONCOS-102,Carboplatin,Cyclophosphamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Targovax Releases Presentations of ONCOS-102 Mesothelioma 24-Month Data

                            Details : ONCOS-102, an immune activators used in combination with Standard of Care (SoC) chemotherapy in patients with malignant pleural mesothelioma clearly shown tumor responses and survival outcomes.

                            Product Name : Undisclosed

                            Product Type : Microorganism

                            Upfront Cash : Inapplicable

                            June 14, 2021

                            Lead Product(s) : ONCOS-102,Carboplatin,Cyclophosphamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Targovax

                            Norway arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Targovax

                            Norway arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Apricoxib

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : IOVaxis Therapeutics

                            Deal Size : $3.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Targovax Grants IOVaxis 3 Months Extension to the Exclusive License Option for TG Mutant RAS Vaccines in Great...

                            Details : Targovax has granted an extension of 3 months to the exclusive option agreement with IOVaxis Therapeutics of Nantong, China, for clinical development and licensing of the Targovax mutant RAS vaccines TG01 and TG02 in China, Hong Kong, Macau and Singapore...

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            June 01, 2021

                            Lead Product(s) : Apricoxib

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : IOVaxis Therapeutics

                            Deal Size : $3.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth